Composition for reducing CD47 expression of cancer cell and increasing phagocytosis of macrophage comprising GV1001 peptide and use of the same
TW202626081APending Publication Date: 2026-07-01GEMVAX & KAEL CO LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- TW114137675
- Authority / Receiving Office
- TW · TW
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-09-29
- Filing Date
- 2025-09-30
- Publication Date
- 2026-07-01
Abstract
The present invention relates to a composition comprising the GV1001 peptide for reducing CD47 expression in cancer cells and increasing macrophage phagocytosis, and to the uses of the same. Specifically, the present invention relates to a composition for use in preventing, treating, or ameliorating cancers associated with CD47 expression, and to the medical use, health functional food use, or feed use of the same. The composition of the present invention exhibits excellent effects in preventing, treating, or ameliorating cancers expressing CD47, particularly head and neck cancer, stomach cancer, and colon cancer, and / or related symptoms.
Need to check novelty before this filing date? Find Prior Art